Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies

Ibrutinib is highly active in treating mantle cell lymphoma (MCL), an aggressive B-cell lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient characteristics on treatment response. Patients with relapsed/refractory MCL (n = 370) treated with ibrutinib had an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Rule, Simon, Dreyling, Martin, Goy, Andre, Hess, Georg, Auer, Rebecca, Kahl, Brad, Cavazos, Nora, Liu, Black, Yang, Shiyi, Clow, Fong, Goldberg, Jenna D., Beaupre, Darrin, Vermeulen, Jessica, Wildgust, Mark, Wang, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5912680/
https://ncbi.nlm.nih.gov/pubmed/28832957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14870
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados